secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001628280-26-017018
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences Q4 net income $20.1M, PBGENE-HBV shows antiviral activity, cash runway through 2028
--------------------------------------------------------------------------------

- Q4 net income $20.1M ($1.05 diluted EPS) vs net loss $17.8M YoY; FY net loss $45.7M ($3.56/sh).
- Cash, equivalents, restricted cash $137.2M as of Dec 31, 2025; $75M Nov 2025 financing extends runway through 2028.
- PBGENE-HBV Phase 1: 13 patients dosed across 5 cohorts; late-breaking data showed safety, dose-dependent antiviral activity and HBsAg declines.
- PBGENE-DMD received IND clearance Feb 2026; Fast Track & Orphan Drug designations; initial data from multiple patients expected year-end 2026.
- Milestone payments: $8M from Imugene (Oct 2025) and $7.5M from TG Therapeutics (Mar 2026).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026017018/0001628280-26-017018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026017018/dtil-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-017018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer